This HTML5 document contains 110 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
wdt	http://www.wikidata.org/prop/direct/
wdtn	http://www.wikidata.org/prop/direct-normalized/
schema	http://schema.org/
skos	http://www.w3.org/2004/02/skos/core#
rdfs	http://www.w3.org/2000/01/rdf-schema#
wikibase	http://wikiba.se/ontology#
p	http://www.wikidata.org/prop/
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
n12	http://dx.doi.org/10.1167/
n10	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdh	http://www.w3.org/2001/XMLSchema#
wds	http://www.wikidata.org/entity/statement/
wd	http://www.wikidata.org/entity/

Statements

Subject Item

wd:Q33555813

rdf:type

wikibase:Item

schema:description

مقالة علمية naučni članak artigo científico scienca artikolo artykuł naukowy scientific article 2010 nî lūn-bûn наукова стаття, опублікована у квітні 2010 2010年论文 מאמר מדעי επιστημονικό άρθρο บทความทางวิทยาศาสตร์ article scientifique (publié 2010) artikull shkencor tudományos cikk 2010年论文 artigo científico (publicado na 2010) мақолаи илмӣ სამეცნიერო სტატია 2010年论文 научна статия 2010年論文 vetenskaplig artikel سائنسی مضمون 2010年の論文 tieteellinen artikkeli 2010年论文 bilimsel makale мақолаи илмӣ ২০১০-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ vědecký článek articol științific научни чланак artículo científico publicado en 2010 مقالهٔ علمی artikulong pang-agham 2010 թվականի ապրիլին հրատարակված գիտական հոդված mokslinis straipsnis vitenskapelig artikkel 2010年論文 2010年论文 videnskabelig artikel (udgivet 2010) wissenschaftlicher Artikel bài báo khoa học article scientific teaduslik artikkel научная статья article científic 2010年論文 2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած 2010年論文 vedecký článok vitskapeleg artikkel 2010년 논문 wetenschappelijk artikel articolo scientifico artigo científico (publicado na 2010) artículu científicu espublizáu en 2010 2010年论文 2010 ഏപ്രില്‍ 14 നു പ്രസിദ്ധീകരിച്ച ശാസ്ത്ര ലേഖനം 2010年論文 научни чланак

p:P577

wds:Q33555813-BF02BCBD-60E4-4FDC-B4CB-CD512956E216

wdt:P577

2010-04-14T00:00:00Z

p:P407

wds:Q33555813-3E9C3F16-C548-43E0-959C-A4EEACE483D8

wdt:P407

wd:Q1860

p:P2093

wds:Q33555813-B862A69A-302B-4F8A-8061-8AE757F98AC7 wds:Q33555813-6C6130DF-7C9B-45F8-9EF6-B93BFABB8F34 wds:Q33555813-84542693-0E98-4D4B-B9BF-E992F4123B2F wds:Q33555813-EF8737B4-C320-4C07-884C-1FF0C67B5B93 wds:Q33555813-01D8029B-1546-479C-8579-984B63452E57

wdt:P2093

David M Urech Tim Streit Tim T Lam T Michael Nork Peter Lichtlen

rdfs:label

Relative contribution of VEGF and TNF-alpha in the cynomolgus laser-induced CNV model: comparing the efficacy of bevacizumab, adalimumab, and ESBA105. Relative contribution of VEGF and TNF-alpha in the cynomolgus laser-induced CNV model: comparing the efficacy of bevacizumab, adalimumab, and ESBA105. Relative contribution of VEGF and TNF-alpha in the cynomolgus laser-induced CNV model: comparing the efficacy of bevacizumab, adalimumab, and ESBA105.

skos:prefLabel

Relative contribution of VEGF and TNF-alpha in the cynomolgus laser-induced CNV model: comparing the efficacy of bevacizumab, adalimumab, and ESBA105. Relative contribution of VEGF and TNF-alpha in the cynomolgus laser-induced CNV model: comparing the efficacy of bevacizumab, adalimumab, and ESBA105. Relative contribution of VEGF and TNF-alpha in the cynomolgus laser-induced CNV model: comparing the efficacy of bevacizumab, adalimumab, and ESBA105.

schema:name

Relative contribution of VEGF and TNF-alpha in the cynomolgus laser-induced CNV model: comparing the efficacy of bevacizumab, adalimumab, and ESBA105. Relative contribution of VEGF and TNF-alpha in the cynomolgus laser-induced CNV model: comparing the efficacy of bevacizumab, adalimumab, and ESBA105. Relative contribution of VEGF and TNF-alpha in the cynomolgus laser-induced CNV model: comparing the efficacy of bevacizumab, adalimumab, and ESBA105.

p:P1476

wds:Q33555813-B758CDFC-65CC-47F2-A134-017C5157E3F7

wdt:P1476

Relative contribution of VEGF and TNF-alpha in the cynomolgus laser-induced CNV model: comparing the efficacy of bevacizumab, adalimumab, and ESBA105.

p:P304

wds:Q33555813-8EA602DD-F3AE-47B4-A6A4-2DC27B360E86

wdt:P304

4738-4745

p:P31

wds:Q33555813-117119C9-D603-4A1B-9D6F-0DC7396F4DFD

wdt:P31

wd:Q13442814

p:P921

wds:Q33555813-9A1FF26B-8F94-49AA-92F4-05828D2C947D wds:Q33555813-3F76B7B3-69C4-401B-9F25-A7715E2E228B wds:Q33555813-52ADD6A7-EB29-4DF3-AA00-463F13767B72

wdt:P921

wd:Q348260 wd:Q413299 wd:Q18032037

p:P698

wds:Q33555813-F09229E6-8C02-49A6-98E2-C9040949192E

wdtn:P698

n10:20393113

wdt:P698

20393113

p:P1433

wds:Q33555813-DDE8C5E2-D08D-4FFA-8846-9F2112F84937

wdt:P1433

wd:Q6060707

p:P433

wds:Q33555813-5770C11A-4377-495F-A3DD-7133DB153E55

p:P478

wds:Q33555813-663DA7D2-D55B-454D-A145-864EF61C325A

wdt:P433

9

wdt:P478

51

p:P356

wds:Q33555813-DD99C2CE-EE13-4F04-9DC0-F8C981F89349

wdtn:P356

n12:IOVS.09-4890

wdt:P356

10.1167/IOVS.09-4890